Research pulse

Vergote et al., 7 September: the immunotherapy plus PARP maintenance question in first line.

Le et al.: the global phase 3 of the PD-1×VEGF bispecific in EGFR-mutant NSCLC, PFS positive with OS not statistically significant.

Dixon-Douglas et al. and a companion APHINITY analysis compare manual, digital, and AI TIL scoring.

Hennequin et al.: higher dose improves progression-free survival.

Zhong et al.: a Chinese Nectin-4 ADC beyond urothelial cancer.

Song et al.: a FAK inhibitor plus a G12C inhibitor, another route around the CRC feedback problem.

Responses in head and neck cancer, strongest in HPV-positive tumours, after 15 years of failed OX40 programmes at big pharma.

Insurance barriers after the daraxonrasib approval.

Louise Emmett and others argue industry is too cautious on dosing frequency; kidney, liver, and marrow toxicity have already ended at least one company.

Politics and science collide as mRNA cancer vaccines regain momentum.

The INTerpath-001 win and the algorithm behind neoantigen selection.

Etcamah approved 4 September after a 6-3 negative advisory vote, on SERENA-6 ctDNA-guided switching data.

First RAS inhibitor for pancreatic cancer, approved 26 August on RASolute 302.

Approved 25 August on HERIZON-GEA-01; a HER2 bispecific plus PD-1 in first line.

The first CELMoD approval, 13 August.

PSMAddition moves radioligand therapy into hormone-sensitive disease, 31 July.

Krämer et al., 3 September: genomics-directed treatment tested in a randomised trial.

Heymach et al., 28 August: longer follow-up of the perioperative PD-L1 regimen.

Caswell-Jin et al., 26 August: the current US recommendations in one document.

Ribas et al.: the triplet's long-term survival, a decade after the doublet era began.

Benefit of the ADC-immunotherapy first line carries into the next line in PD-L1+ TNBC.

Trials show assessment-guided care cuts toxicity; the field now has to deliver it routinely.

Peter Pisters retiring; Jeffrey Lee named interim president.

Extended treatment improves mesorectal-excision-free survival versus short course.

A deal valued over $1 billion for a shelved programme, a sign of ADC demand.

Licensing, a pivotal lung readout, and Treg-directed conjugates.

Sequencing modalities in lymphoma.

Ifinatamab deruxtecan and peers move toward first-line strategies.

About 40% within a year, per the reported analysis.

Camizestrant plus a CDK4/6 inhibitor, accelerated approval.

The pancreatic drug's NEJM lung data.

Lång, 7 September: what the MASAI mammography-AI trial taught about running AI trials.

Loibl et al., 1 September: the randomised phase 3 of PD-L1 blockade in the curative setting.

O'Leary, 20 August: research highlight on vaccination before invasive pancreatic cancer develops.

Arbour et al., 3 September: the pan-RAS inhibitor shows activity beyond pancreatic cancer.

Fathi et al., 3 September: the chemotherapy-free doublet compared head to head with 7+3 in fit patients, with an accompanying editorial.

Mair et al., 13 August: TCR-directed cells against PRAME in a childhood solid tumour.

News digest, 3 September, on the NEJM daraxonrasib NSCLC data.

Machado et al., 1 September: a new mechanism behind the wasting that kills many patients.

Vo et al., 1 September: allelic configuration changes how some variants should be interpreted.

Directly relevant to the NHS-Galleri result and the FDA advisory committee.

Clinical trial results on a practical barrier to repeat CAR-T dosing in glioma.

A radical screening idea at feasibility stage.

Coverage of the NEJM head-to-head with intensive chemotherapy.

Prevention story with policy implications.

563 patients; first phase 3 T-cell engager OS win in first-line maintenance small-cell lung cancer; numbers pending a congress.

The GPRC5D CAR-T advances toward filing.

Buyers target specific modalities and assets rather than platforms.

Forecast to 2036: ADCs, radiopharma, bispecifics, and cell therapy drive growth.

Stroma as a therapeutic target after chemotherapy.

Biomarker work relevant to tarlatamab and DLL3 engagers.

De-escalation guided by gene expression in HR+ disease.

Patient explainer on the TROPION-Breast02 approval.

Camizestrant counted among August's first-in-class approvals.

Sector leaders argue the next decade's defining question is prioritisation, not generation, of candidates.

Symptom-by-symptom guide to treatment-induced menopause.

Twelve new medicines recommended overall; one oncology extension and one sarcoma negative opinion.